Minerva Neurosciences, Inc. (NERV)
Stock Price:
$3.59 USD
-0.06 (-1.64%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
147.93M |
| Revenue (ttm) |
41.18M |
| Net Income (ttm) |
-68.51M |
| Shares Out |
41.20M |
| EPS (ttm) |
-0.68 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$3.59 |
| Previous Close |
$3.65 |
| Change ($) |
-0.06 |
| Change (%) |
-1.64% |
| Day's Open |
3.65 |
| Day's Range |
3.54 - 3.68 |
| Day's Volume |
754,933 |
| 52-Week Range |
1.81 - 15.22 |
More Stats
| Market Cap |
147.93M |
| Enterprise Value |
110.55M |
| Earnings Date (est) |
Nov 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
41.20M |
| Float |
35.76M |
| EPS (basic) |
-1.76 |
| EPS (diluted) |
-0.68 |
| FCF / Share |
-1.10 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
7.00M |
| Short Ratio |
3.72 |
| Short % of Float |
24.35% |
| Beta |
1.52 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.59 |
| PB Ratio |
2.63 |
| Revenue |
41.18M |
| Operating Income |
-71.82M |
| Net Income |
-68.51M |
| Free Cash Flow |
-43.03M |
| Net Cash |
37.37M |
| Net Cash / Share |
0.91 |
| Gross Margin |
n/a |
| Operating Margin |
-174.44% |
| Profit Margin |
n/a |
| FCF Margin |
-104.51% |
| ROA |
-6.98% |
| ROE |
-42.67% |
| ROIC |
-166.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
4 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.90*
(92.20% upside)
Low
3.50
Current: $3.59
High
10.00
Target: 6.90
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | - | - | - | - | - |
| Operating Income | -75.87 | -51.73 | -41.17 | -30.19 | -26.11 | -54.87 | -3.17 |
| Net Income | -72.18 | -50.17 | -31.52 | -31.05 | -27.08 | -56.90 | -3.26 |
| Shares Outstanding | 39.01 | 38.79 | 37.94 | 31.51 | 23.41 | 12.72 | 4.19 |
| Earnings Per Share | -1.85 | -1.29 | -0.83 | -0.99 | -1.16 | -4.47 | -0.78 |
| Operating Cash Flow | -43.43 | -41.94 | 3.09 | -25.69 | -24.27 | -35.96 | -2.16 |
| Capital Expenditures | - | - | -0.05 | - | - | -0.05 | - |
| Free Cash Flow | -43.43 | -41.94 | 3.04 | -25.69 | -24.27 | -36.01 | -2.16 |
| Cash & Equivalents | 45.95 | 88.10 | 128 | 83.06 | 32.28 | 18.58 | 1.82 |
| Total Debt | 0.28 | - | 3.96 | 8.69 | 9.94 | - | 0.06 |
| Net Cash / Debt | 45.67 | 88.10 | 124 | 74.37 | 22.35 | 18.58 | 1.76 |
| Assets | 77.50 | 139 | 184 | 133 | 82.58 | 68.45 | 29.17 |
| Liabilities | 49.72 | 48.87 | 52.10 | 26.96 | 27.26 | 16.95 | 9.00 |
| Book Value | 27.78 | 90.26 | 132 | 106 | 55.32 | 51.50 | 20.18 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Minerva Neurosciences, Inc. |
| Country |
United States |
| Employees |
13 |
| CEO |
Rémy Luthringer |
Stock Information
| Ticker Symbol |
NERV |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NERV |
| IPO Date |
July 1, 2014 |
Description
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the roluperidone worldwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.